Literature DB >> 30849238

Opioid use disorder deaths and the effects of medication therapy.

Paolo Mannelli1, Li-Tzy Wu1,2,3,4.   

Abstract

Entities:  

Keywords:  Buprenorphine; Methadone; Mortality; Naltrexone; Treatment

Mesh：

Substances：

Year:  2019        PMID： 30849238      PMCID： PMC6667376          DOI： 10.1080/00952990.2019.1580289

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN： 0095-2990            Impact factor:   3.912


× No keyword cloud information.
  17 in total

Review 1.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.

Authors:  Erin Kelty; David Joyce; Gary Hulse
Journal:  Am J Drug Alcohol Abuse       Date:  2019-03-08       Impact factor: 3.829

3.  Suicide Deaths With Opioid Poisoning in the United States: 1999-2014.

Authors:  Jennifer Brennan Braden; Mark J Edlund; Mark D Sullivan
Journal:  Am J Public Health       Date:  2017-01-19       Impact factor: 9.308

4.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Authors:  Lars Tanum; Kristin Klemmetsby Solli; Zill-E-Huma Latif; Jurate Šaltyte Benth; Arild Opheim; Kamni Sharma-Haase; Peter Krajci; Nikolaj Kunøe
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

Review 5.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

6.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

7.  Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

Authors:  Evgeny Krupitsky; Edwin Zvartau; Elena Blokhina; Elena Verbitskaya; Valentina Wahlgren; Marina Tsoy-Podosenin; Natalia Bushara; Andrey Burakov; Dmitry Masalov; Tatyana Romanova; Arina Tyurina; Vladimir Palatkin; Tatyana Slavina; Anna Pecoraro; George E Woody
Journal:  Arch Gen Psychiatry       Date:  2012-09

Review 8.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.

Authors:  Luis Sordo; Gregorio Barrio; Maria J Bravo; B Iciar Indave; Louisa Degenhardt; Lucas Wiessing; Marica Ferri; Roberto Pastor-Barriuso
Journal:  BMJ       Date:  2017-04-26

9.  Drug Overdose Deaths Among Women Aged 30-64 Years - United States, 1999-2017.

Authors:  Jacob P VanHouten; Rose A Rudd; Michael F Ballesteros; Karin A Mack
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-01-11       Impact factor: 17.586

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

Authors:  Lawrence Scholl; Puja Seth; Mbabazi Kariisa; Nana Wilson; Grant Baldwin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-04       Impact factor: 17.586
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.